Is ImmuCell Corp. overvalued or undervalued?

As of 17 October 2025, the valuation grade for ImmuCell Corp. has moved from attractive to expensive, indicating a shift towards overvaluation. The company appears to be overvalued, particularly given its negative P/E ratio and low ROCE of -0.63%. Key ratios include a Price to Book Value of 2.05, an EV to EBITDA of 26.30, and an EV to Sales of 2.39, which suggest that the company is trading at a premium relative to its earnings and sales potential.
In comparison to its peers, ImmuCell Corp. has a significantly higher P/E ratio of 33.88, while its closest competitors, such as ImmunoPrecise Antibodies Ltd. and Rani Therapeutics Holdings, Inc., report negative P/E ratios, indicating they are also struggling financially. Over the past year, ImmuCell Corp. has outperformed the S&P 500 with a return of 67.17% compared to the index's 14.08%, but this strong performance may not be sustainable given its current valuation metrics.